[AF] WHO Drug Information Volume 19 No.2

[Martín Cañás]

Estimadas y estimados  colisteros,

esta disponible el:
WHO Drug Information Volume 19  No.2:  
http://www.who.int/druginformation/vol19num2_2005/DI19-2.pdf


Contenidos

( la mayor parte del contenido de la sección de seguridad  está disponble en castellano en la sección Advierten del Boletín Fármacos vol 8  (3) Junio 2005 disponible en http://www.boletinfarmacos.org/062005/coverpage.htm)

Biomedicines  Update International nomenclature and gene therapy products 101

 
Safety and Efficacy Issues
Tiagabin: seizures in  patients without a history of epilepsy 108
Effect of medroxyprogesterone on  bone mineral density 108
Tumour necrosis factor inhibitors: safety update  109
Pimecrolimus and tacrolimus linked to cancer increase  110
Erythropoietin: caution in cancer patients 110
Oxcarbazepine:  multi-organ sensitivity 111
Drotrecogin alfa: single organ dysfunction  111
Drotrecogin alfa: not indicated for paeditric sepsis 112
Interferon  beta–1a and hepatic injury 113
Avascular necrosis with interferon–2b in  chronic myelogenous leukaemia 113
Hylan G–F20: joint inflammation and pain  114
Galantamine and vascular events 114
Rosuvastatin: revised start doses  115
New kidney function test a better predictor of risk 115
Statins and  peripheral neuropathy 115
Angioedema: still a problem with ACE inhibitors  116
More advice on SSRI use 117
Million Women Study: latest HRT data  117
Tuberculin purified protein derivative (Mantoux) and serious allergic  reactions 118
Ezetimibe: hepatic, muscle and pancreatic reactions  118
Mefloquine: revised patient information 119
Atomoxatine and liver  injury 119
Gefitinib: failure to show survival in lung cancer  119
 
Regulatory Action and News
Progress in  defining borderline pharmaceutical products 121
Temozolomide approved for  glioblastoma multiforme 121
Pramlintide approved for diabetes  122
Entecavir approved for chronic hepatitis B 122
DNA–based test approved  to detect cystic fibrosis 123
Nataluzimab: marketing withdrawal pending  evaluation 123
Rosiglitazone (Nyracta®): voluntary withdrawal 123
Risk  management legislation 124
New pharmacogenomics guidance  124
 
Current Topics
WHO clinical trial registration initiative  126
International registration of trial information: Ottawa statement  128
Disclosure of information on clinical trials 129
Forecasting  antiretroviral and diagnostic needs 129
 
ATC/DDD  Classification
Temporary list 131
Final list 133

y también  el:

Proposed International Nonproprietary Names: List 93 
http://www.who.int/druginformation/vol19num2_2005/P-List93.pdf
 
Saludos,
 
Martín
 
Martín Cañás
GAPURMED La Plata  (Argentina)
macanas en netverk.com.ar